acute lymphoblastic leukemia (Cancer)
Information
- Disease name
- acute lymphoblastic leukemia
- Disease ID
- DOID:9952
- Description
- "A acute leukemia that is characterized by over production of lymphoblasts." [url:http\://www.cancer.gov/dictionary?CdrID=46332]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04340154 | Active, not recruiting | Phase 2 | Study of Sequential CAR-T Cell Treating Leukemia Children | May 1, 2020 | November 1, 2024 |
| NCT03178617 | Active, not recruiting | N/A | High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma | February 14, 2018 | December 15, 2024 |
| NCT03147612 | Active, not recruiting | Phase 2 | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | February 8, 2018 | February 28, 2025 |
| NCT03434730 | Active, not recruiting | Phase 2 | Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation | February 7, 2018 | February 7, 2025 |
| NCT01494103 | Active, not recruiting | Phase 1 | Administration of Donor T Cells With the Caspase-9 Suicide Gene | November 2011 | May 2029 |
| NCT02003222 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | May 19, 2014 | December 4, 2024 |
| NCT01503632 | Active, not recruiting | Phase 3 | Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission | February 21, 2012 | December 31, 2029 |
| NCT03821610 | Active, not recruiting | Phase 2 | A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) | November 22, 2018 | November 22, 2027 |
| NCT05515029 | Active, not recruiting | Phase 3 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis | August 23, 2022 | October 16, 2026 |
| NCT01044069 | Active, not recruiting | Phase 1 | Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | January 5, 2010 | January 2025 |
| NCT00003861 | Active, not recruiting | Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia | April 1999 | ||
| NCT00476190 | Active, not recruiting | Phase 2 | ALL Adult Consortium Trial: Adult ALL Trial | April 2007 | December 2024 |
| NCT03117751 | Active, not recruiting | Phase 2/Phase 3 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | March 29, 2017 | March 31, 2028 |
| NCT03333486 | Active, not recruiting | Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | December 7, 2017 | August 28, 2024 |
| NCT00719888 | Active, not recruiting | Phase 2 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | November 18, 2005 | December 22, 2024 |
| NCT04329325 | Active, not recruiting | Phase 2 | Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | March 30, 2020 | March 2025 |
| NCT02143414 | Active, not recruiting | Phase 2 | Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia | June 30, 2015 | October 23, 2024 |
| NCT00048958 | Active, not recruiting | Cytogenetic Studies in Acute Leukemia and Multiple Myeloma | June 1984 | ||
| NCT05687032 | Active, not recruiting | Phase 4 | A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | February 24, 2023 | November 7, 2025 |
| NCT03114865 | Active, not recruiting | Phase 1/Phase 2 | A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | September 5, 2017 | June 30, 2025 |
| NCT01574274 | Active, not recruiting | Phase 2 | SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma | June 2012 | July 2027 |
| NCT01593488 | Active, not recruiting | Phase 2 | Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children | March 2012 | December 2024 |
| NCT05774990 | Active, not recruiting | Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment | April 1, 2023 | August 2025 | |
| NCT03301168 | Active, not recruiting | Phase 1/Phase 2 | Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant | April 2014 | May 2034 |
| NCT02256137 | Active, not recruiting | A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer | October 8, 2014 | August 17, 2025 | |
| NCT03642626 | Active, not recruiting | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | December 18, 2018 | June 1, 2028 | |
| NCT04233346 | Active, not recruiting | Phase 2 | The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation | July 9, 2020 | December 31, 2025 |
| NCT02996773 | Active, not recruiting | Phase 1 | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine | November 29, 2016 | August 25, 2025 |
| NCT04191187 | Active, not recruiting | Phase 2 | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies | December 6, 2019 | February 2025 |
| NCT00557193 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | January 15, 2008 | June 28, 2024 |
| NCT05326516 | Active, not recruiting | Phase 1 | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | March 9, 2022 | June 2024 |
| NCT02315612 | Active, not recruiting | Phase 1 | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies | December 12, 2014 | June 1, 2040 |
| NCT05972577 | Active, not recruiting | N/A | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | June 2, 2021 | December 31, 2024 |
| NCT01139970 | Active, not recruiting | Phase 1 | Veliparib and Temozolomide in Treating Patients With Acute Leukemia | May 21, 2010 | February 22, 2025 |
| NCT03904134 | Active, not recruiting | N/A | Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) | June 14, 2019 | March 2025 |
| NCT03844048 | Active, not recruiting | Phase 3 | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | September 6, 2019 | May 27, 2025 |
| NCT03204916 | Active, not recruiting | Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia | December 18, 2017 | September 30, 2024 | |
| NCT04105530 | Active, not recruiting | N/A | Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) | November 18, 2019 | September 2024 |
| NCT02881086 | Active, not recruiting | Phase 3 | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | August 2016 | July 2025 |
| NCT02443831 | Active, not recruiting | Phase 1 | CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies | April 2016 | December 31, 2036 |
| NCT05386576 | Active, not recruiting | Early Phase 1 | A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | June 16, 2022 | May 2025 |
| NCT00136435 | Active, not recruiting | Phase 2 | A Study in Adults With Untreated Acute Lymphoblastic Leukemia | June 2002 | July 2024 |
| NCT02494882 | Active, not recruiting | Phase 1 | Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older | June 29, 2015 | June 2025 |
| NCT01744223 | Active, not recruiting | Phase 1/Phase 2 | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | March 2013 | October 2032 |
| NCT01424982 | Active, not recruiting | Phase 2 | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | October 5, 2011 | October 31, 2025 |
| NCT04060277 | Active, not recruiting | Phase 2 | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | November 27, 2019 | April 7, 2030 |
| NCT04473911 | Active, not recruiting | Phase 1 | Haplo Peripheral Blood Sct In GVHD Prevention | August 14, 2020 | October 2024 |
| NCT00792948 | Active, not recruiting | Phase 2 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia | September 1, 2009 | January 6, 2025 |
| NCT00710892 | Active, not recruiting | Phase 1 | CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene | December 2008 | July 2026 |
| NCT01190930 | Active, not recruiting | Phase 3 | Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma | August 9, 2010 | March 31, 2028 |
| NCT02553460 | Active, not recruiting | Phase 1/Phase 2 | Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I | January 29, 2016 | October 2031 |
| NCT04943952 | Approved for marketing | JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase | |||
| NCT05776134 | Available | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel | |||
| NCT00552825 | Completed | Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children | October 2005 | October 2006 | |
| NCT00560794 | Completed | Phase 2 | Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) | January 2008 | November 2014 |
| NCT00576472 | Completed | Phase 4 | Learning Impairments Among Survivors of Childhood Cancer | January 2000 | March 2010 |
| NCT04888468 | Completed | Phase 1 | Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | November 5, 2019 | September 1, 2021 |
| NCT00600977 | Completed | Phase 2 | Liposomal Anthracyclin in the Treatment of Elderly ALL | March 2002 | October 2006 |
| NCT00602134 | Completed | N/A | Bioequivalence Study of 6-Mercaptopurine Under Fasting Conditions | November 2002 | November 2002 |
| NCT00606216 | Completed | Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy | January 2007 | December 2015 | |
| NCT04843514 | Completed | TDM of Asparaginase in ALL2008 | April 1, 2021 | January 31, 2024 | |
| NCT00659425 | Completed | Phase 1 | CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma | September 2008 | December 2014 |
| NCT00664131 | Completed | Neurologic Morbidity and Disability in Acute Lymphoblastic Leukemia Survivors | August 2005 | October 2008 | |
| NCT00671034 | Completed | Phase 3 | Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia | July 21, 2008 | March 31, 2021 |
| NCT00671658 | Completed | Phase 2 | Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia | November 2002 | July 2013 |
| NCT04843150 | Completed | Pharmacokinetics and Immunogenicity of the First Doses of PEG-Asparaginase -An ALLTogether Pilot Study | July 1, 2020 | October 1, 2023 | |
| NCT00678275 | Completed | Phase 3 | Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia | October 2006 | March 2015 |
| NCT00682305 | Completed | Phase 2 | Allogeneic Stem Cell Transplantation (SCT) With Treosulfan, VP-16 and Cyclophosphamid for Patients With Acute Lymphoblastic Leukemia (ALL) | March 2007 | August 2013 |
| NCT00686556 | Completed | Phase 1 | Total Marrow Irradiation for Refractory Acute Leukemia | August 2012 | December 2016 |
| NCT00693602 | Completed | Phase 1 | Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma | June 2006 | December 2011 |
| NCT00697671 | Completed | Phase 1 | Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies | March 2007 | May 2013 |
| NCT00718757 | Completed | Phase 1 | Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies | January 2005 | January 2009 |
| NCT00719147 | Completed | AVN of Weight-Bearing Joints In Patients With Hematologic Malignancies Treated With Dexamethasone Or Prednisone | July 2001 | July 2005 | |
| NCT00720109 | Completed | Phase 2/Phase 3 | Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | July 14, 2008 | March 31, 2020 |
| NCT00723099 | Completed | Phase 2 | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | June 25, 2008 | July 31, 2018 |
| NCT00723346 | Completed | Phase 1/Phase 2 | Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia | January 2006 | March 2009 |
| NCT00726934 | Completed | N/A | The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients | September 2007 | January 2017 |
| NCT00750659 | Completed | Phase 2 | Nilotinib Pre and Post Allogeneic Stem Cell Transplantation | July 2009 | April 2016 |
| NCT00766311 | Completed | N/A | Aerobic and Strengthening Exercise for Acute Leukemia | January 2008 | December 2011 |
| NCT04825548 | Completed | Post-thrombotic Syndrome After Deep Venous Thrombosis (DVT) in Patients Treated According to the NOPHO ALL2008 Protocol | July 1, 2020 | December 31, 2023 | |
| NCT00784017 | Completed | Phase 3 | Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemia | October 2008 | October 2012 |
| NCT00789776 | Completed | Phase 1/Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | October 13, 2008 | May 2017 |
| NCT04699162 | Completed | Efficacy of Intermediate and High Intensity Regimens in Patients With Relapsed Acute Lymphoblastic Leukemia | July 1, 2016 | December 31, 2020 | |
| NCT00795756 | Completed | Phase 2/Phase 3 | Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia | January 2008 | October 2013 |
| NCT00795886 | Completed | Phase 2 | Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL) | August 2005 | March 2010 |
| NCT04666025 | Completed | SARS-CoV-2 Donor-Recipient Immunity Transfer | September 23, 2020 | May 5, 2023 | |
| NCT00807677 | Completed | Phase 1 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | March 2009 | March 2013 |
| NCT00816049 | Completed | Phase 3 | ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy | January 2009 | March 2, 2016 |
| NCT00819351 | Completed | Phase 3 | ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase | January 1, 2009 | March 2, 2016 |
| NCT04629430 | Completed | N/A | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT | February 19, 2021 | October 28, 2022 |
| NCT00853008 | Completed | Phase 4 | Treatment of High Risk Adult Acute Lymphoblastic Leukemia | January 2003 | December 2012 |
| NCT00861679 | Completed | N/A | Therapy Protocol Acute Lymphoblastic Leukemia Stem Cell Transplantation International | January 2007 | September 2014 |
| NCT00862719 | Completed | Phase 2 | Sitagliptin Umbilical Cord Blood Transplant Study | March 2009 | February 2015 |
| NCT04524455 | Completed | Phase 1 | Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL | October 2, 2020 | January 24, 2023 |
| NCT00866307 | Completed | Phase 1 | Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011) | February 23, 2009 | March 31, 2021 |
| NCT00874562 | Completed | Phase 1 | Rapamycin in Relapsed Acute Lymphoblastic Leukemia | July 2007 | April 2016 |
| NCT00890656 | Completed | Phase 2 | Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage | June 2003 | January 2011 |
| NCT04452604 | Completed | Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19 | September 11, 2020 | July 7, 2021 | |
| NCT00902213 | Completed | N/A | Physical Activity to Modify Sequelae and Quality of Life in Childhood Acute Lymphoblastic Leukemia | November 2009 | May 2015 |
| NCT00911066 | Completed | Phase 1 | MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia | June 2009 | October 2013 |
| NCT00930098 | Completed | Phase 2 | A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia | December 2003 | July 2007 |
| NCT00940524 | Completed | Phase 1 | Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia | July 2009 | April 2014 |
| NCT00945828 | Completed | N/A | Assessing the Effectiveness of Individual Education Plans for Childhood Cancer Survivors | January 2003 | October 2010 |
| NCT00954720 | Completed | Observational Study of Iron Overload in Stem Cell Transplantation | March 2008 | May 2011 | |
| NCT04323657 | Completed | Phase 1/Phase 2 | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | March 27, 2020 | February 24, 2023 |
| NCT00964873 | Completed | Phase 1 | A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia | August 2009 | August 2011 |
| NCT04187248 | Completed | The Association Between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in NOPHOALL 2008 | July 1, 2008 | March 1, 2017 | |
| NCT04145531 | Completed | Phase 2/Phase 3 | An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) | December 27, 2019 | July 13, 2022 |
| NCT00973752 | Completed | Phase 2 | Treatment of Older Adults With Acute Lymphoblastic Leukemia | August 2009 | April 2016 |
| NCT04082286 | Completed | Phase 1 | Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia | May 2016 | May 14, 2020 |
| NCT00990249 | Completed | Phase 2 | Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | October 2009 | May 2016 |
| NCT04067518 | Completed | Phase 2 | A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia | October 17, 2019 | February 4, 2022 |
| NCT01004497 | Completed | Phase 2 | First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL | March 2010 | April 2015 |
| NCT01014195 | Completed | Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors | January 2010 | October 2014 | |
| NCT01015261 | Completed | Phase 2/Phase 3 | Allogenic Bone Marrow Transplantation (BMT) Compare With Cytoreduction and Chemotherapy in Acute Lymphoblastic Leukemia (ALL) Patients | October 2008 | September 2010 |
| NCT01025778 | Completed | Phase 2 | Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia | December 2009 | December 2012 |
| NCT01036009 | Completed | Phase 2 | A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies | October 2009 | July 2015 |
| NCT01047020 | Completed | Motor Proficiency And Physical Activity in Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) | June 2009 | April 2013 | |
| NCT01051154 | Completed | Phase 2 | Effect of Enteral Docosahexaenoic Acid Administration in Children With Acute Lymphoblastic Leukemia | September 2010 | August 2016 |
| NCT01068301 | Completed | Phase 1 | A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation | May 2010 | October 2013 |
| NCT01077544 | Completed | Phase 1 | A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) | April 14, 2011 | July 1, 2015 |
| NCT04015882 | Completed | N/A | Effects of Exercises on Total Body Health in Children With Acute Lymphoblastic Leukemia | August 1, 2019 | December 31, 2019 |
| NCT04014764 | Completed | Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy | December 15, 2019 | March 31, 2022 | |
| NCT01094392 | Completed | Hemostasis During Asparaginase Treatment in Acute Lymphoblastic Leukemia(ALL) | March 2010 | October 10, 2018 | |
| NCT01095926 | Completed | Phase 2 | Pharmacokinetic Study of Doxorubicin in Children With Cancer | May 2010 | May 2013 |
| NCT04007601 | Completed | N/A | Neurostimulation In Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) | December 12, 2019 | June 21, 2023 |
| NCT01110473 | Completed | Phase 1 | ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies | April 2010 | June 2013 |
| NCT01119066 | Completed | Phase 2 | HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | May 3, 2010 | March 30, 2021 |
| NCT01134575 | Completed | Phase 2 | CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) | June 4, 2010 | April 18, 2018 |
| NCT01142427 | Completed | Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | August 9, 2010 | September 30, 2023 | |
| NCT03964259 | Completed | Phase 1 | Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia | October 2, 2019 | December 28, 2022 |
| NCT01148927 | Completed | Quality of Life Study for Adult Patients With Acute Lymphoblastic Leukemia | November 2009 | October 2012 | |
| NCT01149915 | Completed | Phase 1 | Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias | June 2010 | August 2013 |
| NCT01159028 | Completed | Phase 1 | Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS | June 2010 | March 30, 2017 |
| NCT01169012 | Completed | Phase 1 | PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias | September 2010 | January 2013 |
| NCT01184885 | Completed | Early Phase 1 | A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | July 2010 | April 2013 |
| NCT03919526 | Completed | Phase 1 | Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL | August 11, 2019 | November 1, 2023 |
| NCT01188798 | Completed | Phase 3 | Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies | September 2010 | February 2012 |
| NCT01196013 | Completed | Phase 1 | A Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia | August 2010 | May 2011 |
| NCT01217996 | Completed | N/A | Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors | October 2010 | November 2013 |
| NCT03803670 | Completed | Clinical Significance of Occult Central Nervous System Disease In Adult Acute Lymphoblastic Leukemia | January 1, 2007 | January 10, 2019 | |
| NCT01231412 | Completed | Phase 3 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | November 2010 | June 30, 2017 |
| NCT01253720 | Completed | N/A | PACE CALL: Weight Loss Study for Childhood Leukemia Survivors | June 2008 | June 2013 |
| NCT01256398 | Completed | Phase 2 | Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | December 14, 2010 | November 15, 2021 |
| NCT01266083 | Completed | Phase 2 | WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) | December 2010 | February 2018 |
| NCT01279473 | Completed | Phase 1/Phase 2 | Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study) | August 2005 | |
| NCT01297543 | Completed | Phase 1/Phase 2 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia | March 2011 | January 2015 |
| NCT03677596 | Completed | Phase 4 | A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients | July 1, 2019 | May 26, 2023 |
| NCT01324180 | Completed | Phase 1 | Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) | July 18, 2011 | July 27, 2017 |
| NCT01324336 | Completed | Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets | July 2011 | December 2013 | |
| NCT03581045 | Completed | Postural Control Under Different Cognitive Loads in Adult Survivors of Acute Lymphoblastic Leukemia and Age-Matched Healthy Individuals | October 2, 2018 | April 27, 2021 | |
| NCT03575325 | Completed | Phase 2 | Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia | October 11, 2018 | September 14, 2023 |
| NCT03555955 | Completed | Phase 1 | A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 | November 20, 2018 | May 26, 2021 |
| NCT01358253 | Completed | Phase 4 | Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia | December 2010 | December 2012 |
| NCT01363128 | Completed | Phase 2 | Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | July 12, 2011 | April 8, 2020 |
| NCT01364363 | Completed | N/A | Unrelated Donor Stem Cell Transplantation | March 2005 | July 2015 |
| NCT03476239 | Completed | Phase 3 | Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | October 18, 2017 | April 8, 2021 |
| NCT01380587 | Completed | Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia | November 2010 | September 2012 | |
| NCT01393249 | Completed | PEG-Asparaginase Associated Pancreatitis, Hepatotoxicity and Hyperlipidemia in Children With ALL | July 2011 | June 2014 | |
| NCT01439217 | Completed | Endothelial Function, Arterial Stiffness and Components | June 2011 | February 2013 | |
| NCT01457040 | Completed | Phase 2/Phase 3 | Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia | October 2011 | December 2016 |
| NCT01462253 | Completed | Phase 2 | Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults | October 2012 | March 11, 2017 |
| NCT01466179 | Completed | Phase 2 | Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | December 2011 | January 2017 |
| NCT01470924 | Completed | Acute Lymphoblastic Leukemia Relapse in Sweden 2003-2007 | January 2003 | June 2011 | |
| NCT01471782 | Completed | Phase 1/Phase 2 | Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | January 2012 | May 2016 |
| NCT01476462 | Completed | Second Malignant Neoplasms After Childhood ALL Therapy | January 2009 | December 2011 | |
| NCT03471416 | Completed | Nutritional Status in Children With ALL in Guatemala | May 1, 2019 | September 1, 2022 | |
| NCT01506453 | Completed | Phase 2 | Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) | January 24, 2012 | January 2, 2018 |
| NCT03429387 | Completed | N/A | PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia | January 8, 2018 | January 23, 2021 |
| NCT01517035 | Completed | Phase 1/Phase 2 | Improving Blood Stem Cell Collection and Transplant Procedures | January 13, 2012 | March 29, 2017 |
| NCT01523782 | Completed | Phase 2 | Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia | April 2009 | October 2012 |
| NCT01523977 | Completed | Phase 1 | Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL | November 2011 | November 2018 |
| NCT01540812 | Completed | Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS | February 2012 | December 1, 2019 | |
| NCT01556386 | Completed | Pharmacogenetic Analysis of Korean Pediatric Patients With Acute Lymphoblastic Leukemia | June 2006 | May 2012 | |
| NCT01564784 | Completed | Phase 3 | A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia | August 2, 2012 | January 4, 2017 |
| NCT01565447 | Completed | Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma Gait Parameters Study | December 2011 | March 20, 2023 | |
| NCT01611298 | Completed | N/A | Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR | March 2008 | July 2013 |
| NCT01641107 | Completed | Phase 2 | Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. | December 4, 2014 | September 30, 2021 |
| NCT01643408 | Completed | Phase 2 | A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy | November 2012 | December 2013 |
| NCT01643668 | Completed | Phase 2 | Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation | July 2012 | August 2016 |
| NCT01663129 | Completed | Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study | January 2005 | March 6, 2014 | |
| NCT03267186 | Completed | Phase 2 | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant | September 12, 2017 | April 30, 2021 |
| NCT01678508 | Completed | Pharmacogenetically Based Dosing of Thiopurines in Childhood Acute Lymphoblastic Leukemia | January 2002 | February 2012 | |
| NCT01684150 | Completed | Phase 1 | A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving | September 2012 | February 2016 |
| NCT03267030 | Completed | Phase 2 | Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase | August 23, 2017 | October 22, 2020 |
| NCT03190499 | Completed | Quality of Life in Children With Cancer | August 1, 2017 | August 1, 2018 | |
| NCT01696461 | Completed | Phase 2 | A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor | May 2013 | August 2016 |
| NCT01697020 | Completed | Phase 1 | Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions | September 2012 | November 2012 |
| NCT01713582 | Completed | Phase 1 | A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) | December 14, 2012 | January 20, 2017 |
| NCT01756118 | Completed | Phase 1 | A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia | June 2012 | February 7, 2020 |
| NCT01766804 | Completed | N/A | Effect of Bovine Colostrum on Toxicity and Inflammatory Responses | March 2013 | December 2016 |
| NCT01794299 | Completed | Phase 2 | Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor | March 2013 | September 2017 |
| NCT01795378 | Completed | Phase 1/Phase 2 | Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation | February 2013 | May 2015 |
| NCT01810120 | Completed | Phase 1/Phase 2 | Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT | January 2012 | December 2016 |
| NCT01842672 | Completed | Phase 1/Phase 2 | Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia | March 2013 | September 2022 |
| NCT01854567 | Completed | Phase 3 | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies | August 2013 | May 5, 2017 |
| NCT03187977 | Completed | N/A | Cognitive Intervention at the End of Therapy for Survivors of Childhood ALL Treated on TOTXVI | August 3, 2017 | October 13, 2021 |
| NCT01886651 | Completed | The Influence of Thiopurine Methyltransferase Activity on Toxicity After High-dose Methotrexate in Childhood Acute Lymphoblastic Leukemia | July 2011 | February 2012 | |
| NCT01943682 | Completed | Phase 1 | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | September 2013 | April 2019 |
| NCT01951885 | Completed | Phase 3 | Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention | July 7, 2014 | August 11, 2021 |
| NCT02003612 | Completed | Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia | October 1, 2013 | April 28, 2014 | |
| NCT03147365 | Completed | N/A | Effect of Different Exercises on Quality of Life of Leukemia Patients. | March 5, 2017 | April 5, 2020 |
| NCT02010931 | Completed | Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients | September 2013 | June 2014 | |
| NCT02042690 | Completed | Phase 3 | Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients | July 2014 | April 2019 |
| NCT03123939 | Completed | Phase 3 | Phase III B in Acute Lymphoblastic Leukemia | April 24, 2017 | October 13, 2020 |
| NCT03118128 | Completed | N/A | Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia | January 1, 2015 | April 30, 2017 |
| NCT02086773 | Completed | Phase 1 | Red Cell Transfusion Goals in Patients With Acute Leukemias | April 2014 | September 2015 |
| NCT02099266 | Completed | N/A | Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment | June 2013 | February 2016 |
| NCT02118324 | Completed | N/A | Exergaming Intervention in ALL Patients | March 2014 | January 2016 |
| NCT02181478 | Completed | Early Phase 1 | Intra-Osseous Co-Transplant of UCB and hMSC | July 22, 2015 | February 7, 2020 |
| NCT02185781 | Completed | Phase 1 | Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) | January 28, 2015 | November 29, 2021 |
| NCT02188290 | Completed | Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation | September 2014 | June 2015 | |
| NCT03096782 | Completed | Phase 2 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | October 13, 2017 | September 20, 2022 |
| NCT02228772 | Completed | Phase 1 | Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults | December 2014 | November 2019 |
| NCT03023046 | Completed | Phase 2 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | February 23, 2017 | May 1, 2022 |
| NCT03005392 | Completed | Phase 1/Phase 2 | Home-exercise Program for Children and Adolescent Survivors of Acute Lymphoblastic Leukemia | June 2015 | March 2016 |
| NCT02272673 | Completed | The Effects of Honey on Febrile Neutropenia in Children With Acute Lymphoblastic Leukemia | March 2011 | September 2014 | |
| NCT02295839 | Completed | N/A | Sleep Hygiene and Relaxation Intervention to Improve Sleep and Fatigue for Children Receiving Maintenance Chemotherapy | May 2011 | August 2014 |
| NCT02960646 | Completed | Phase 1 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | January 18, 2017 | February 13, 2023 |
| NCT02912676 | Completed | Phase 1/Phase 2 | Thiopurine EnhAnced Maintenance Therapy | October 2016 | April 2020 |
| NCT02336282 | Completed | N/A | Treatment for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia | January 12, 2015 | July 20, 2017 |
| NCT02890758 | Completed | Phase 1 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | May 22, 2018 | February 17, 2023 |
| NCT02340884 | Completed | Phase 2 | A Pilot RCT of the PRISM Intervention for AYAs With Cancer | January 30, 2015 | December 19, 2021 |
| NCT02369653 | Completed | Phase 3 | A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase | October 22, 2015 | July 7, 2021 |
| NCT02373579 | Completed | Phase 2 | Effect of Omega-3 Fatty Acids on Methotrexate Induced Hepatotoxicity in Children With Acute Lymphoblastic Leukemia | June 2012 | October 2014 |
| NCT02447718 | Completed | Phase 4 | Vaccinating Children After Chemotherapy | November 16, 2015 | March 5, 2018 |
| NCT02862652 | Completed | N/A | Role of the Microparticles and of Tissue Factor in the Pro-thrombotic Phenotype and the Thromboembolic Complications During the Acute Lymphoblastic Leukemia in Children. | May 2014 | March 21, 2017 |
| NCT02500550 | Completed | Phase 2 | Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor | October 9, 2015 | December 17, 2018 |
| NCT02847130 | Completed | Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology | November 21, 2016 | June 30, 2023 | |
| NCT02813252 | Completed | Long-Term Follow-up Study for Patients Previously Treated With JCAR015 | August 30, 2016 | October 22, 2021 | |
| NCT02529813 | Completed | Phase 1 | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | December 16, 2015 | November 8, 2021 |
| NCT02807883 | Completed | Phase 2 | Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia | August 2016 | February 1, 2022 |
| NCT02779283 | Completed | Phase 1 | Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia | January 13, 2016 | September 20, 2018 |
| NCT02544438 | Completed | Phase 1/Phase 2 | Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | September 2015 | September 20, 2017 |
| NCT02544789 | Completed | Phase 2 | Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia | June 2009 | May 2012 |
| NCT02566395 | Completed | Phase 3 | Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies | December 2014 | February 14, 2022 |
| NCT00003838 | Completed | Phase 2 | Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | April 15, 1999 | June 18, 2020 |
| NCT02743351 | Completed | Phase 1/Phase 2 | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | December 20, 2016 | November 5, 2021 |
| NCT02639559 | Completed | Phase 2 | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | March 31, 2016 | April 7, 2023 |
| NCT00015587 | Completed | Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study) | April 1995 | July 2016 | |
| NCT00026780 | Completed | Eligibility Screening for a NCI Pediatric Oncology Branch Research Study | September 24, 2001 | October 7, 2020 | |
| NCT00075725 | Completed | Phase 3 | Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia | December 29, 2003 | March 31, 2021 |
| NCT00096161 | Completed | Phase 2 | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant | May 2003 | August 2015 |
| NCT00103285 | Completed | Phase 3 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | April 11, 2005 | March 31, 2021 |
| NCT00130195 | Completed | Phase 2 | Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) | September 2002 | May 2008 |
| NCT00143559 | Completed | Phase 2 | Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies | August 2005 | January 2009 |
| NCT00144677 | Completed | Phase 2 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation | November 2003 | June 2006 |
| NCT00144703 | Completed | Phase 2 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation | July 2002 | November 2006 |
| NCT00144963 | Completed | Phase 1/Phase 2 | Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | July 2002 | August 2006 |
| NCT06338020 | Completed | N/A | Adaptive Variable-Resistance Training in Pediatric Survivors of Acute Lymphoblastic Leukemia | December 29, 2022 | January 4, 2024 |
| NCT00165178 | Completed | Phase 3 | Treatment of Acute Lymphoblastic Leukemia in Children | September 2000 | May 2011 |
| NCT00171249 | Completed | Phase 2 | An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia | August 9, 1999 | September 23, 2013 |
| NCT00184041 | Completed | Phase 2 | Intensified Post Remission Therapy Containing PEG-Asparaginase | July 2004 | December 2012 |
| NCT00186875 | Completed | Phase 2 | Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia | November 2003 | August 2016 |
| NCT06195735 | Completed | Forecasting Hypersensitivity Against PEG-asparaginase to Optimize Outcome in ALL | July 17, 2020 | December 21, 2023 | |
| NCT00187083 | Completed | Phase 3 | A Study of Children With Refractory or Relapsed ALL | February 1997 | December 2003 |
| NCT00222027 | Completed | Phase 2 | Feasibility of Risk-Adapted Therapy in Young Adult Acute Lymphoblastic Leukemia: a Multicenter Trial | November 2003 | December 2008 |
| NCT00270881 | Completed | Phase 1/Phase 2 | Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies | January 2006 | January 2011 |
| NCT00285259 | Completed | Phase 2 | Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | January 31, 2006 | November 30, 2010 |
| NCT00287105 | Completed | Phase 2 | Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children | December 2005 | March 3, 2017 |
| NCT00300664 | Completed | Phase 2/Phase 3 | A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. | July 2002 | April 2005 |
| NCT00315705 | Completed | Phase 1/Phase 2 | A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias. | March 2006 | May 2010 |
| NCT05679817 | Completed | N/A | How Effective is the Dose-graded Aerobic Training in Children Survivors of Acute Lymphoblastic Leukemia? | October 3, 2021 | November 24, 2022 |
| NCT05563545 | Completed | Phase 1 | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia | July 21, 2022 | November 25, 2022 |
| NCT00358072 | Completed | Phase 2 | Treatment of Adult ALL With an MRD-directed Programme. | May 2000 | September 2008 |
| NCT00368355 | Completed | Phase 2 | T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts | April 2000 | November 2016 |
| NCT00374933 | Completed | Phase 1 | Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation | April 2007 | December 2009 |
| NCT00376467 | Completed | Phase 2 | STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia | December 2001 | February 2011 |
| NCT00378534 | Completed | Phase 2 | Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | September 2006 | April 2014 |
| NCT00388193 | Completed | Phase 2 | Rituximab Combined With Chemotherapy in Burkitt's Lymphoma | August 2006 | December 2013 |
| NCT00388895 | Completed | Phase 2 | Glivec in Ph Positive Lymphoblastic Leukemia | June 2002 | October 2007 |
| NCT00390793 | Completed | Phase 2 | Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | September 28, 2006 | February 2, 2024 |
| NCT00411541 | Completed | Phase 4 | Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia | April 1995 | January 2004 |
| NCT00412243 | Completed | Phase 1/Phase 2 | Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients | March 2006 | April 2012 |
| NCT00435864 | Completed | N/A | Natural Killer Index From Hematopoietic Stem Cell Graft | April 2007 | November 2013 |
| NCT05433532 | Completed | Phase 2 | Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients | May 1, 2022 | April 13, 2024 |
| NCT00440726 | Completed | Phase 1/Phase 2 | Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) | August 4, 2006 | February 26, 2011 |
| NCT00460694 | Completed | Phase 1/Phase 2 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies | August 2006 | December 2012 |
| NCT00466895 | Completed | Phase 1 | Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. | April 2007 | July 2016 |
| NCT00494897 | Completed | Phase 4 | PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia | June 1996 | December 2007 |
| NCT00505141 | Completed | Urban Environmental Exposures and Childhood Cancer | September 2004 | February 2006 | |
| NCT00513175 | Completed | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia | October 2001 | November 2007 | |
| NCT04956666 | Completed | Phase 2 | A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL) | June 15, 2021 | January 23, 2023 |
| NCT04954326 | Completed | Phase 2 | A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL) | May 7, 2021 | May 20, 2022 |
| NCT00526175 | Completed | Phase 4 | LAL-BR/2001: Study Treatment to Low Risk ALL | June 2001 | December 2015 |
| NCT00526305 | Completed | Phase 4 | LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive | January 2000 | April 2005 |
| NCT00526409 | Completed | Phase 4 | LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia | June 2005 | October 2014 |
| NCT00529360 | Completed | Phase 1/Phase 2 | Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL | June 2007 | March 2016 |
| NCT00539695 | Completed | Phase 2 | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD | June 2007 | March 2014 |
| NCT00549848 | Completed | Phase 3 | Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | October 29, 2007 | March 26, 2022 |
| NCT02646839 | Enrolling by invitation | Phase 2 | KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | October 2015 | August 2024 |
| NCT00923442 | Enrolling by invitation | Biology Studies of Hematologic Cancers | February 24, 2004 | ||
| NCT03226704 | Enrolling by invitation | Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing | August 14, 2017 | July 31, 2030 | |
| NCT02197650 | No longer available | Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase | |||
| NCT01200017 | No longer available | Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant | |||
| NCT03594162 | No longer available | Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch | |||
| NCT05054465 | Not yet recruiting | Phase 1/Phase 2 | A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL | October 1, 2021 | August 1, 2026 |
| NCT06323044 | Not yet recruiting | N/A | MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence | June 15, 2024 | June 15, 2029 |
| NCT06242353 | Not yet recruiting | Coagulopathy in Childhood Acute Lymphoblastic Leukaemia | March 1, 2024 | November 2028 | |
| NCT06128070 | Not yet recruiting | Phase 2 | Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | June 14, 2024 | October 31, 2027 |
| NCT03932903 | Not yet recruiting | N/A | Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia | March 1, 2024 | August 31, 2024 |
| NCT06160115 | Not yet recruiting | The Role of NK Cells to Detect Blood Infection in ALL. | February 1, 2024 | April 1, 2025 | |
| NCT06308588 | Not yet recruiting | Phase 2 | Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | September 30, 2024 | May 2029 |
| NCT06289673 | Not yet recruiting | Phase 4 | Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | July 2024 | May 2039 |
| NCT06452732 | Not yet recruiting | Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML | June 15, 2024 | June 30, 2026 | |
| NCT05968170 | Not yet recruiting | N/A | TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant | December 1, 2023 | July 1, 2035 |
| NCT06350994 | Not yet recruiting | Early Assessment of Cardiac Function After Treatment With CAR-T Cells | September 2024 | January 2027 | |
| NCT05521087 | Not yet recruiting | Phase 1 | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias | December 26, 2025 | January 29, 2030 |
| NCT05025774 | Not yet recruiting | Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise | September 1, 2024 | August 1, 2025 | |
| NCT05381181 | Not yet recruiting | Phase 1 | Safety and Efficacy Evaluation of Next-generation CD19-UCART | December 20, 2023 | May 3, 2026 |
| NCT05223686 | Not yet recruiting | Phase 1 | To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. | February 10, 2022 | March 10, 2025 |
| NCT06291428 | Not yet recruiting | Raman Spectroscopy Compared to Flow Cytometry | October 15, 2024 | December 30, 2026 | |
| NCT06287944 | Not yet recruiting | Phase 1 | 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | June 18, 2024 | February 24, 2027 |
| NCT04092348 | Not yet recruiting | FoxO3a and PU.1 in Acute Lymphoblastic Leukemia | August 1, 2023 | December 30, 2024 | |
| NCT06087419 | Not yet recruiting | Phase 1/Phase 2 | A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients | October 30, 2023 | December 30, 2025 |
| NCT05751044 | Not yet recruiting | Phase 1/Phase 2 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | October 1, 2023 | October 1, 2030 |
| NCT06461091 | Not yet recruiting | the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic Leukemia | June 2024 | April 30, 2025 | |
| NCT06446661 | Not yet recruiting | N/A | Using Text Messages to Improve Oral Chemotherapy for Adolescents and Young Adults With Acute Lymphoblastic Leukemia | June 15, 2024 | June 15, 2028 |
| NCT04888741 | Recruiting | Phase 2 | Methods of T Cell Depletion Trial (MoTD) | February 22, 2021 | January 2026 |
| NCT04904588 | Recruiting | Phase 2 | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide | September 30, 2021 | July 2024 |
| NCT06367725 | Recruiting | Pharmacokinetics of Dexamethasone in Childhood ALL and Reduction in Bone Mineral Density | April 11, 2024 | December 30, 2030 | |
| NCT03286634 | Recruiting | Phase 2 | ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 | April 18, 2017 | March 31, 2033 |
| NCT05442515 | Recruiting | Phase 1/Phase 2 | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | December 28, 2022 | July 1, 2029 |
| NCT04975555 | Recruiting | Phase 2 | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy | November 15, 2021 | December 31, 2025 |
| NCT05014165 | Recruiting | Backtracking Leukemia-Typical Somatic Mutations in Cord Blood | August 25, 2021 | September 30, 2026 | |
| NCT05031897 | Recruiting | Phase 2 | Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | October 25, 2021 | October 1, 2024 |
| NCT05428176 | Recruiting | N/A | A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors | February 16, 2023 | June 30, 2027 |
| NCT05400122 | Recruiting | Phase 1 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | September 9, 2022 | June 1, 2026 |
| NCT05139004 | Recruiting | Phase 1 | 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | July 19, 2022 | December 13, 2024 |
| NCT05153330 | Recruiting | Phase 1 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | January 24, 2022 | March 31, 2025 |
| NCT05252403 | Recruiting | Phase 2 | Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL | December 1, 2021 | March 2025 |
| NCT05268003 | Recruiting | Phase 2 | A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia | June 7, 2022 | October 5, 2026 |
| NCT05375617 | Recruiting | European Prospective Investigation Into Childhood Cancer | July 7, 2023 | March 1, 2031 | |
| NCT06144606 | Recruiting | Phase 2 | Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) | December 26, 2023 | November 15, 2028 |
| NCT05326919 | Recruiting | The Patient Cohort of the National Center for Precision Medicine in Leukemia | March 28, 2022 | March 2042 | |
| NCT05364762 | Recruiting | Phase 2 | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | November 23, 2022 | April 28, 2024 |
| NCT05327894 | Recruiting | Phase 3 | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia | December 15, 2022 | September 2030 |
| NCT05334069 | Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | August 1, 2022 | February 2025 | |
| NCT05334823 | Recruiting | Phase 2 | A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | January 26, 2022 | July 1, 2025 |
| NCT02300961 | Recruiting | N/A | Feasibility Neurocognitive Outcome After Transplant | December 1, 2014 | September 2026 |
| NCT03314974 | Recruiting | Phase 2 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | March 30, 2018 | November 10, 2025 |
| NCT03318770 | Recruiting | Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | May 10, 2019 | May 2024 | |
| NCT06125106 | Recruiting | Phase 1 | Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab | November 16, 2023 | February 1, 2026 |
| NCT06093334 | Recruiting | N/A | Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD | October 17, 2023 | December 2024 |
| NCT03399773 | Recruiting | Phase 2 | Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes | May 10, 2022 | June 30, 2026 |
| NCT03422731 | Recruiting | Early Phase 1 | Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy | February 15, 2018 | November 6, 2024 |
| NCT02716233 | Recruiting | Phase 3 | A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents | April 2016 | April 2026 |
| NCT03441061 | Recruiting | Phase 2 | Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease | February 15, 2018 | February 28, 2025 |
| NCT03448393 | Recruiting | Phase 1 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | March 26, 2018 | December 31, 2040 |
| NCT06059391 | Recruiting | Phase 2 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | August 30, 2024 | January 1, 2028 |
| NCT03494569 | Recruiting | Phase 1 | Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome | July 6, 2018 | November 11, 2028 |
| NCT03533816 | Recruiting | Phase 1 | Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | January 31, 2020 | January 2025 |
| NCT06025682 | Recruiting | Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO | April 4, 2024 | January 2025 | |
| NCT03564678 | Recruiting | Phase 2 | Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia | May 17, 2018 | December 31, 2036 |
| NCT03568266 | Recruiting | Pharmacogenomics of Asparaginase Induced Hepatotoxicity | May 22, 2018 | May 22, 2026 | |
| NCT03571321 | Recruiting | Phase 1 | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | May 28, 2019 | September 5, 2027 |
| NCT06013423 | Recruiting | Phase 2 | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | July 6, 2024 | October 31, 2025 |
| NCT02727803 | Recruiting | Phase 2 | Personalized NK Cell Therapy in CBT | May 19, 2016 | May 31, 2025 |
| NCT03622788 | Recruiting | Phase 1/Phase 2 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | August 8, 2019 | December 1, 2025 |
| NCT06001385 | Recruiting | Phase 2 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | December 8, 2023 | June 30, 2026 |
| NCT05969002 | Recruiting | Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias | August 25, 2023 | April 30, 2026 | |
| NCT03007147 | Recruiting | Phase 3 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | August 8, 2017 | September 30, 2027 |
| NCT03016377 | Recruiting | Phase 1/Phase 2 | Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | March 22, 2012 | April 22, 2041 |
| NCT02670564 | Recruiting | Phase 4 | ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) | April 2013 | April 2026 |
| NCT03765177 | Recruiting | Phase 1/Phase 2 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies | October 16, 2019 | October 31, 2037 |
| NCT03779854 | Recruiting | Phase 2 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | August 29, 2019 | December 31, 2025 |
| NCT05963971 | Recruiting | N/A | A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors | June 23, 2023 | June 23, 2027 |
| NCT03802695 | Recruiting | Phase 1 | A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | April 8, 2019 | April 2028 |
| NCT06299462 | Recruiting | Phase 1/Phase 2 | PTCy and ATG for MSD and MUD Transplants | June 20, 2024 | June 1, 2031 |
| NCT03810196 | Recruiting | N/A | CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT | March 1, 2019 | January 2026 |
| NCT03856216 | Recruiting | Phase 2 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation | October 28, 2019 | March 31, 2025 |
| NCT06408194 | Recruiting | Phase 1 | Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies | May 13, 2024 | June 2025 |
| NCT05950204 | Recruiting | N/A | Effect of Supplementation With ω-3 Fatty Acids, Vitamin D and Calcium in Patients With Acute Lymphoblastic Leukemia. | September 10, 2022 | December 31, 2024 |
| NCT05929976 | Recruiting | InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort | October 26, 2022 | October 1, 2029 | |
| NCT05918692 | Recruiting | Phase 1 | A Phase 1, Study of BMF-500 in Adults With Acute Leukemia | July 26, 2023 | July 31, 2026 |
| NCT02047578 | Recruiting | Phase 2 | Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL. | February 5, 2014 | December 2023 |
| NCT03913559 | Recruiting | Phase 2 | Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia | May 14, 2019 | January 2025 |
| NCT05887167 | Recruiting | Phase 1 | Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies | March 2, 2024 | December 15, 2026 |
| NCT03934372 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | January 29, 2020 | January 4, 2025 |
| NCT03960840 | Recruiting | Phase 1/Phase 2 | Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL | June 26, 2019 | June 30, 2027 |
| NCT03970096 | Recruiting | Phase 2 | Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | November 19, 2019 | December 31, 2028 |
| NCT05866887 | Recruiting | N/A | Insomnia Prevention in Children With Acute Lymphoblastic Leukemia | September 26, 2023 | October 1, 2024 |
| NCT05811845 | Recruiting | Mercaptopurine Therapeutic Drug Monitoring to Optimize the Maintenance Phase of Childhood ALL | July 30, 2022 | December 31, 2026 | |
| NCT05809167 | Recruiting | Phase 2 | Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT | January 20, 2022 | January 20, 2026 |
| NCT05800210 | Recruiting | Phase 2 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | May 3, 2024 | May 2027 |
| NCT05793463 | Recruiting | Anti-mullerian Hormone in Acute Lymphoblastic Leukemia | February 15, 2018 | March 15, 2024 | |
| NCT05772000 | Recruiting | Clinical Significance of Occult Central Nervous System Localization | September 8, 2020 | September 8, 2024 | |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT04049383 | Recruiting | Phase 1 | CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL | October 16, 2020 | June 1, 2026 |
| NCT04065399 | Recruiting | Phase 1/Phase 2 | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | November 5, 2019 | December 2024 |
| NCT02508038 | Recruiting | Phase 1 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | February 12, 2016 | December 2025 |
| NCT06277011 | Recruiting | Early Phase 1 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research | February 10, 2023 | May 15, 2025 |
| NCT04532268 | Recruiting | Early Phase 1 | A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL | August 23, 2020 | August 23, 2026 |
| NCT04537871 | Recruiting | Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study | November 18, 2020 | December 4, 2024 | |
| NCT05579132 | Recruiting | Phase 1/Phase 2 | A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia | September 30, 2022 | July 31, 2025 |
| NCT04606433 | Recruiting | Phase 1 | Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | November 4, 2020 | November 2024 |
| NCT05578378 | Recruiting | Phase 2/Phase 3 | Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL | January 1, 2022 | December 31, 2024 |
| NCT04635384 | Recruiting | Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test | June 30, 2021 | December 31, 2024 | |
| NCT05541341 | Recruiting | Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies | November 24, 2023 | December 16, 2038 | |
| NCT05535855 | Recruiting | Phase 1 | UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 | January 24, 2024 | July 2027 |
| NCT04684563 | Recruiting | Phase 1 | huCART19-IL18 in NHL/CLL Patients | May 6, 2021 | May 2036 |
| NCT04689204 | Recruiting | Early Phase 1 | A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies | December 29, 2020 | May 31, 2027 |
| NCT03263572 | Recruiting | Phase 2 | Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | November 29, 2017 | November 30, 2025 |
| NCT04726241 | Recruiting | Phase 1/Phase 2 | The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | April 18, 2022 | December 31, 2026 |
| NCT04732845 | Recruiting | Phase 1 | Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies | April 26, 2021 | December 1, 2024 |
| NCT04747912 | Recruiting | Phase 2 | Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) | March 2, 2021 | May 1, 2026 |
| NCT04764513 | Recruiting | Phase 1/Phase 2 | Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT | September 12, 2021 | April 2025 |
| NCT04787263 | Recruiting | Phase 1/Phase 2 | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML | March 4, 2021 | March 3, 2038 |
| NCT04811560 | Recruiting | Phase 1/Phase 2 | A Study of JNJ-75276617 in Participants With Acute Leukemia | May 19, 2021 | February 16, 2026 |
| NCT05519579 | Recruiting | Phase 2 | Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia | June 30, 2023 | August 1, 2025 |
| NCT04817761 | Recruiting | Phase 2/Phase 3 | SPARK-ALL: Calaspargase Pegol in Adults With ALL | July 7, 2021 | February 2027 |
| NCT05501899 | Recruiting | Early Phase 1 | Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia | March 3, 2023 | December 31, 2023 |
| NCT06195891 | Recruiting | Phase 1 | Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome | September 28, 2024 | June 21, 2027 |
| NCT06392581 | Recruiting | Observational Study on Invasive Fungal Infection Incidence in Ph-neg Acute Lymphoblastic Leukemia Patients | April 14, 2022 | June 14, 2024 | |
| NCT05457556 | Recruiting | Phase 3 | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome | March 15, 2023 | December 1, 2027 |
| NCT04872478 | Recruiting | Phase 1 | Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL | April 1, 2022 | December 31, 2024 |
| NCT03275493 | Recruiting | Phase 1/Phase 2 | CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia | July 1, 2017 | December 31, 2025 |
| NCT00898755 | Recruiting | Collecting and Storing Tissue From Young Patients With Cancer | March 5, 2007 | ||
| NCT05581030 | Recruiting | Phase 1 | CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | May 1, 2023 | November 2027 |
| NCT06209190 | Recruiting | N/A | Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation | September 1, 2023 | August 31, 2024 |
| NCT04532203 | Recruiting | Early Phase 1 | A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies | November 1, 2020 | November 1, 2026 |
| NCT04532281 | Recruiting | Early Phase 1 | A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies | November 1, 2020 | November 1, 2026 |
| NCT05763290 | Recruiting | Childhood Cancer Survivors' Affective Response to Exercise | March 22, 2023 | December 2024 | |
| NCT06227026 | Recruiting | Phase 1 | Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies | February 20, 2024 | January 15, 2027 |
| NCT05748171 | Recruiting | Phase 2 | A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL | May 17, 2023 | July 9, 2031 |
| NCT05739227 | Recruiting | Early Phase 1 | Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies | March 1, 2023 | May 2025 |
| NCT05735717 | Recruiting | Phase 2 | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | May 11, 2023 | November 30, 2030 |
| NCT04179929 | Recruiting | N/A | Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults | November 25, 2019 | February 2027 |
| NCT06220487 | Recruiting | Phase 2 | A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL | February 1, 2024 | January 1, 2028 |
| NCT05694364 | Recruiting | Phase 1 | Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies | January 25, 2023 | January 2026 |
| NCT04195633 | Recruiting | Phase 2 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | January 25, 2021 | December 31, 2026 |
| NCT05657652 | Recruiting | N/A | CAV Regimen for R/R Ph- B-ALL | October 1, 2022 | October 2024 |
| NCT06393335 | Recruiting | Early Phase 1 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research | May 15, 2024 | March 15, 2026 |
| NCT05639673 | Recruiting | Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic Leukemia | June 15, 2023 | November 1, 2025 | |
| NCT04227015 | Recruiting | Early Phase 1 | A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy | January 8, 2020 | May 31, 2027 |
| NCT02872987 | Recruiting | GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial | February 2009 | December 2030 | |
| NCT04262843 | Recruiting | Phase 2 | Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia | February 7, 2020 | August 4, 2025 |
| NCT05621291 | Recruiting | N/A | A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu... | June 23, 2024 | December 31, 2025 |
| NCT04322084 | Recruiting | Continuous Ambulatory Monitoring to Predict Elevated Risk of Infection in Children With Lymphoblastic Leukemia Undergoing Induction Chemotherapy (CAMPER-ALL) | June 2024 | July 2025 | |
| NCT05618041 | Recruiting | N/A | The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies | September 7, 2022 | December 6, 2024 |
| NCT03246906 | Recruiting | Phase 2 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | September 11, 2017 | October 11, 2026 |
| NCT04340167 | Recruiting | Phase 2 | Study of Anti-CD22 CAR-T Cells Treating Leukemia Children | May 1, 2020 | October 1, 2024 |
| NCT05589896 | Recruiting | Phase 1/Phase 2 | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | March 30, 2024 | August 2025 |
| NCT05587582 | Recruiting | Behavioral Parenting Skills As A Novel Target for Improving Pediatric Medication Adherence | September 1, 2022 | November 30, 2026 | |
| NCT00991744 | Suspended | Phase 3 | Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL) | January 2009 | December 2018 |
| NCT03128034 | Suspended | Phase 1/Phase 2 | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia | October 24, 2017 | March 31, 2027 |
| NCT04151706 | Suspended | Phase 2 | CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML | February 27, 2020 | February 2026 |
| NCT03326921 | Suspended | Phase 1 | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | February 23, 2018 | July 16, 2028 |
| NCT04928599 | Suspended | Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States | March 14, 2022 | March 31, 2028 | |
| NCT00593554 | Terminated | Phase 2 | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies | August 7, 2007 | July 28, 2017 |
| NCT02588092 | Terminated | Phase 1 | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) | February 1, 2016 | August 29, 2018 |
| NCT02535806 | Terminated | Phase 2 | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults | July 2015 | May 25, 2017 |
| NCT02535364 | Terminated | Phase 2 | Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) | August 21, 2015 | September 1, 2017 |
| NCT02518750 | Terminated | Phase 2 | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma | November 23, 2016 | March 11, 2018 |
| NCT02404220 | Terminated | Phase 1/Phase 2 | Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | May 6, 2015 | December 17, 2018 |
| NCT02991898 | Terminated | Phase 2 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | February 16, 2017 | June 20, 2019 |
| NCT02999854 | Terminated | Phase 3 | Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer | November 29, 2017 | December 17, 2021 |
| NCT02257684 | Terminated | Phase 2 | A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar) | September 2014 | January 2016 |
| NCT02231853 | Terminated | Phase 1 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections | September 3, 2014 | December 29, 2017 |
| NCT02065869 | Terminated | Phase 1/Phase 2 | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | April 2014 | September 7, 2021 |
| NCT01910428 | Terminated | Phase 1 | L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL | October 2013 | March 2018 |
| NCT03195010 | Terminated | Phase 2 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | June 9, 2017 | December 21, 2018 |
| NCT01685411 | Terminated | N/A | Busulfan and Cyclophosphamide Followed By ALLO BMT | January 2013 | February 10, 2020 |
| NCT01685021 | Terminated | Phase 2 | Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) | April 2013 | March 2015 |
| NCT03272633 | Terminated | Early Phase 1 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | October 26, 2020 | September 22, 2022 |
| NCT03286114 | Terminated | Phase 1 | Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab | December 21, 2017 | April 28, 2021 |
| NCT01621477 | Terminated | Phase 2 | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | August 2012 | December 2015 |
| NCT01532635 | Terminated | Phase 2 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives | March 2012 | May 2013 |
| NCT01486043 | Terminated | N/A | Metformin and Transient Hyperglycemia | December 2011 | May 2013 |
| NCT01483690 | Terminated | Phase 1/Phase 2 | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | December 2011 | July 31, 2015 |
| NCT01326728 | Terminated | Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation | March 30, 2011 | July 14, 2017 | |
| NCT01312818 | Terminated | Phase 2 | Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) | June 2011 | January 2013 |
| NCT03668392 | Terminated | Phase 2 | Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL) | June 25, 2020 | December 31, 2021 |
| NCT01300611 | Terminated | Phase 1 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation | January 2011 | December 2020 |
| NCT03705507 | Terminated | Phase 1/Phase 2 | International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia | May 18, 2018 | May 3, 2023 |
| NCT03733249 | Terminated | Phase 1/Phase 2 | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | January 2017 | April 14, 2023 |
| NCT03742323 | Terminated | Phase 1/Phase 2 | REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia | July 1, 2018 | June 2, 2020 |
| NCT01230788 | Terminated | N/A | Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia | September 2010 | October 2012 |
| NCT01207076 | Terminated | Phase 1 | AHN-12 Biodistribution in Advanced Leukemia | December 2013 | July 2014 |
| NCT03860844 | Terminated | Phase 2 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | August 6, 2019 | May 26, 2023 |
| NCT01195480 | Terminated | Phase 1/Phase 2 | CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL) | May 2012 | November 2015 |
| NCT01187810 | Terminated | Phase 1 | Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | August 2010 | April 2018 |
| NCT01148134 | Terminated | Pharmacokinetic Profile of Vincristine Administered With Imatinib for Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) Compared to That Without Imatinib for Bcr-Abl Negative ALL | June 2010 | April 2012 | |
| NCT01001390 | Terminated | N/A | The Effects of Ankle Foot Orthoses on Gait Efficiency in Children With Acute Lymphoblastic Leukemia and Foot Drop | October 2009 | June 2011 |
| NCT00983528 | Terminated | Phase 1/Phase 2 | Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia | September 2009 | September 2011 |
| NCT04083170 | Terminated | Phase 2 | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers | October 6, 2022 | November 30, 2022 |
| NCT04095858 | Terminated | Phase 3 | Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) | January 5, 2021 | November 5, 2021 |
| NCT00968864 | Terminated | Phase 2 | T-cell Depleted Alternative Donor Transplantation | August 2009 | November 2016 |
| NCT00967525 | Terminated | N/A | Intraosseous Infusion of Unrelated Cord Blood Grafts | March 2007 | July 2011 |
| NCT04225676 | Terminated | Phase 2 | Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) | October 19, 2020 | October 19, 2021 |
| NCT00961142 | Terminated | Phase 2 | Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia | June 2009 | December 30, 2015 |
| NCT00944008 | Terminated | Phase 3 | PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia | September 2009 | July 2012 |
| NCT00905398 | Terminated | Phase 1/Phase 2 | Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | May 2009 | July 2015 |
| NCT00866281 | Terminated | Phase 1/Phase 2 | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia | September 2009 | September 2014 |
| NCT00790855 | Terminated | Phase 1/Phase 2 | Bendamustine in Acute Leukemia and MDS | November 2008 | March 2012 |
| NCT04762875 | Terminated | Phase 2 | MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies | June 16, 2021 | March 14, 2022 |
| NCT00674427 | Terminated | Phase 1 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant | January 2008 | January 2012 |
| NCT00658411 | Terminated | N/A | Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation | August 2008 | December 2011 |
| NCT02669264 | Terminated | Phase 1 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) | March 2016 | July 3, 2018 |
| NCT00579111 | Terminated | Phase 1/Phase 2 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | June 2007 | October 2010 |
| NCT00522990 | Terminated | Phase 1/Phase 2 | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | September 2006 | April 2009 |
| NCT00514722 | Terminated | N/A | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies | October 2002 | March 2009 |
| NCT00513318 | Terminated | Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies | August 2004 | June 2009 | |
| NCT05410574 | Terminated | N/A | Family-Based Behavioral Treatment for Childhood Survivors of Acute Lymphoblastic Leukemia | July 22, 2022 | March 26, 2024 |
| NCT00439296 | Terminated | Phase 1/Phase 2 | ABT-751 With Chemotherapy for Relapsed Pediatric ALL | May 22, 2006 | September 23, 2009 |
| NCT00346632 | Terminated | Phase 1 | An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia | June 2006 | April 2008 |
| NCT00276159 | Terminated | Phase 2 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | January 2006 | November 2008 |
| NCT00187005 | Terminated | Phase 3 | Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | July 1998 | July 2002 |
| NCT00165087 | Terminated | Phase 3 | Treatment of Childhood Acute Lymphoblastic Leukemia | January 1996 | September 2006 |
| NCT02339350 | Unknown status | Phase 2 | Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children | January 2015 | April 2023 |
| NCT02451774 | Unknown status | Phase 2/Phase 3 | Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction | January 2015 | December 2020 |
| NCT04969601 | Unknown status | Phase 1/Phase 2 | Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings | September 29, 2021 | March 29, 2023 |
| NCT03318419 | Unknown status | Phase 2 | Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia | January 1, 2016 | December 31, 2020 |
| NCT03298828 | Unknown status | Phase 1 | CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | November 2017 | October 2022 |
| NCT03278145 | Unknown status | Dependence Receptors and Leukemia | November 2017 | November 2019 | |
| NCT02744768 | Unknown status | Phase 2 | D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia | May 31, 2017 | June 2021 |
| NCT03249636 | Unknown status | New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia | December 2017 | October 2019 | |
| NCT01873807 | Unknown status | Phase 4 | HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL | May 2013 | December 2015 |
| NCT01906671 | Unknown status | Phase 4 | Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid | June 2013 | November 2018 |
| NCT02007811 | Unknown status | Phase 1/Phase 2 | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination | November 2013 | December 2015 |
| NCT02070523 | Unknown status | Phase 3 | Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia: | December 2013 | December 2015 |
| NCT02186860 | Unknown status | Phase 1 | Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia | July 2016 | December 2021 |
| NCT03027739 | Unknown status | Phase 2/Phase 3 | CART-19 Cells For MRD Positive CD19+ ALL | November 2016 | December 2020 |
| NCT02290132 | Unknown status | ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors | August 2013 | July 2017 | |
| NCT02965092 | Unknown status | Phase 1/Phase 2 | CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | December 2, 2015 | December 2021 |
| NCT02310243 | Unknown status | Phase 1/Phase 2 | Study of Palbociclib in MLL-rearranged Acute Leukemias | July 2015 | July 2019 |
| NCT05326984 | Unknown status | N/A | Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia | February 9, 2021 | December 2023 |
| NCT00439920 | Unknown status | Phase 2 | GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL. | October 1996 | December 2018 |
| NCT05133310 | Unknown status | Phase 4 | Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia | November 19, 2021 | June 23, 2023 |
| NCT00774332 | Unknown status | Phase 2 | A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL | June 2006 | December 2009 |
| NCT00402090 | Unknown status | DHPLC Determination of TPMT Polymorphisms. | April 2005 | November 2006 | |
| NCT04814004 | Unknown status | Phase 1 | Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors | March 19, 2021 | April 1, 2024 |
| NCT04796688 | Unknown status | Phase 1 | Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies | March 10, 2021 | March 10, 2024 |
| NCT04677231 | Unknown status | Evaluation of Long-term Health Status and Quality of Life in Adult Survivors With Philadelphia-negative Acute Lymphoblastic Leukemia/Lymphoma Treated With an Intensive Pediatric or Pediatric-inspired Protocol | January 2021 | March 2024 | |
| NCT00797810 | Unknown status | Phase 4 | Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults | December 2006 | |
| NCT00846703 | Unknown status | Phase 4 | The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia | July 2008 | December 2018 |
| NCT04554381 | Unknown status | Phase 1 | Assesment of JL1 Expression in Acute Leukemia | October 13, 2020 | November 2023 |
| NCT04488237 | Unknown status | Vitamin D and Methotrexate Adverse Effects | September 2020 | December 2021 | |
| NCT04364451 | Unknown status | Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Eukaemia During Therapy With L - Asparaginase. | September 1, 2019 | August 31, 2022 | |
| NCT04226989 | Unknown status | Early Phase 1 | A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy | February 5, 2020 | May 31, 2024 |
| NCT04206943 | Unknown status | Phase 1/Phase 2 | Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL | October 12, 2019 | January 1, 2021 |
| NCT00328237 | Unknown status | Phase 2 | Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation | November 2005 | |
| NCT00961285 | Unknown status | Genotyping Analysis of Acute Lymphoblastic Leukemia | March 2009 | December 2012 | |
| NCT04168788 | Unknown status | N/A | Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL | January 1, 2020 | January 1, 2022 |
| NCT04158011 | Unknown status | A Retrospective Study of Patients With Leukemia Relapse in the CNS Treated With CAR T Cells | November 6, 2019 | January 1, 2021 | |
| NCT04154709 | Unknown status | Phase 1 | CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia | December 10, 2019 | June 2022 |
| NCT00982514 | Unknown status | Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008 | September 2009 | December 2014 | |
| NCT04096846 | Unknown status | Effect of Vitamin D Diffiency on Oral Mucosa in Patients Recieving Methotrexate Chemotherapy | November 1, 2019 | December 1, 2020 | |
| NCT01079507 | Unknown status | Genome-wide Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Lymphoblastic Leukemia | February 2010 | ||
| NCT02810223 | Unknown status | Phase 1 | Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia | May 2016 | |
| NCT00222612 | Unknown status | Phase 4 | Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 | October 2003 | August 2013 |
| NCT01089907 | Unknown status | Genomic Changes in Childhood Acute Lymphoblastic Leukemia | April 2010 | June 2013 | |
| NCT04008251 | Unknown status | Phase 1 | Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | May 27, 2019 | December 31, 2022 |
| NCT04007978 | Unknown status | Phase 1 | Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies | August 5, 2019 | December 30, 2022 |
| NCT01104324 | Unknown status | Osteonecrosis in Children With Acute Lymphoblastic Leukemia | July 2009 | December 2012 | |
| NCT03920813 | Unknown status | Phase 4 | Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy | January 2015 | December 2021 |
| NCT03902197 | Unknown status | Phase 2 | CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients | April 22, 2019 | December 21, 2023 |
| NCT03898128 | Unknown status | ItaliaN Observational Study of Patients With Acute Lymphoblastic Leukemia Treated With Anti-CD22 Immunoconjugate | November 27, 2019 | September 2021 | |
| NCT03887156 | Unknown status | Phase 2/Phase 3 | Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft | September 16, 2019 | March 16, 2023 |
| NCT03798509 | Unknown status | Phase 1 | Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia | March 13, 2019 | January 2024 |
| NCT03655145 | Unknown status | Phase 3 | HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation | August 2018 | June 2023 |
| NCT00192673 | Unknown status | Phase 4 | Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses | June 2005 | December 2013 |
| NCT01354457 | Unknown status | Phase 1/Phase 2 | Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+ | November 2010 | June 2016 |
| NCT01358201 | Unknown status | Phase 4 | PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years | May 2010 | December 2022 |
| NCT01366898 | Unknown status | Phase 4 | Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years) | June 30, 2007 | December 2022 |
| NCT01513603 | Unknown status | Phase 2 | Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia | January 2012 | January 2014 |
| NCT03366350 | Unknown status | Phase 1/Phase 2 | Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies | April 15, 2016 | June 1, 2021 |
| NCT03366324 | Unknown status | Phase 1/Phase 2 | Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies | May 1, 2016 | June 1, 2021 |
| NCT04845035 | Withdrawn | Phase 2 | Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | January 2024 | January 2029 |
| NCT02815059 | Withdrawn | Phase 1 | Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone | September 28, 2016 | January 9, 2018 |
| NCT05168748 | Withdrawn | Phase 1 | CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia | January 24, 2023 | August 13, 2026 |
| NCT03628053 | Withdrawn | Phase 3 | Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia | June 5, 2020 | January 7, 2026 |
| NCT05037669 | Withdrawn | Phase 1 | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma | July 2022 | January 2038 |
| NCT03982992 | Withdrawn | Phase 2 | Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab | June 1, 2019 | November 30, 2021 |
| NCT03141398 | Withdrawn | Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology Group | August 2017 | December 2018 | |
| NCT00349518 | Withdrawn | Phase 2/Phase 3 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | December 2006 | |
| NCT01677949 | Withdrawn | Phase 2 | Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia | December 2013 | January 2016 |
| NCT02632903 | Withdrawn | Phase 2 | Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study | October 2016 | August 20, 2018 |
| NCT01688752 | Withdrawn | Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia | |||
| NCT00900445 | Withdrawn | Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia | March 24, 2008 | ||
| NCT05321940 | Withdrawn | Phase 1 | Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias | November 30, 2023 | November 30, 2026 |
| NCT00957320 | Withdrawn | Phase 1 | Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL) | June 2009 | August 2012 |
| NCT04282174 | Withdrawn | Phase 2 | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies | September 2022 | March 1, 2030 |
| NCT03768310 | Withdrawn | Phase 1 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) | June 2022 | August 2040 |
| NCT03187691 | Withdrawn | Phase 2 | Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia | August 2019 | December 2020 |
- Disase is a (Disease Ontology)
- DOID:12603
- Cross Reference ID (Disease Ontology)
- EFO:0000220
- Cross Reference ID (Disease Ontology)
- GARD:522
- Cross Reference ID (Disease Ontology)
- ICD10CM:C91.00
- Cross Reference ID (Disease Ontology)
- ICD9CM:204.0
- Cross Reference ID (Disease Ontology)
- MIM:247640
- Cross Reference ID (Disease Ontology)
- MIM:613065
- Cross Reference ID (Disease Ontology)
- NCI:C3167
- Cross Reference ID (Disease Ontology)
- NCI:C7055
- Cross Reference ID (Disease Ontology)
- ORDO:513
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:128822004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0023449
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1335469
- Exact Synonym (Disease Ontology)
- acute lymphoblastic leukaemia
- Exact Synonym (Disease Ontology)
- acute lymphocytic leukaemia
- Exact Synonym (Disease Ontology)
- ALL
- Exact Synonym (Disease Ontology)
- precursor lymphoblastic lymphoma/leukemia
- HPO alt_id (Human Phenotype Ontology)
- HP:0004803
- HPO alt_id (Human Phenotype Ontology)
- HP:0005555
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0006721
- OrphaNumber from OrphaNet (Orphanet)
- 513